摘要
目的探讨鳖甲软肝片(BRT)联合恩替卡韦(ETV)治疗慢性乙型肝炎(CHB)的临床效果。方法选取2016年9月至2018年12月在宜春市人民医院就诊的174例CHB患者作为研究对象,采用随机数字表法将其分为对照组与观察组,每组各87例。对照组患者采用ETV治疗,观察组患者采用ETV联合BRT治疗。比较两组患者的肝脏炎症分级、肝脏纤维化分级、HBV DNA拷贝量、血清谷丙转氨酶(ALT)及肝纤维化指标[透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)、层粘蛋白(LN)]水平。结果治疗第48周时,两组患者的肝脏炎症分级优于本组治疗前,差异有统计学意义(P<0.05);治疗第48周时,两组患者肝脏炎症分级比较,差异无统计学意义(P>0.05)。治疗第48周时,观察组患者的肝脏纤维化分级优于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者的血清ALT、HA、PCⅢ、Ⅳ-C、LN水平比较,差异无统计学意义(P>0.05);治疗第48周时,两组患者的血清ALT、HA、PCⅢ、Ⅳ-C和LN水平低于治疗前,差异有统计学意义(P<0.05);治疗第48周时,观察组患者的血清ALT、HA、PCⅢ、Ⅳ-C、LN水平低于对照组,差异有统计学意义(P<0.05)。两组患者治疗前、治疗第12周、治疗第24周、治疗第48周时的HBV DNA拷贝量比较,差异均无统计学意义(P>0.05)。结论BRT抗肝纤维化是CHB的有效辅助治疗方式,对改善患者肝纤维化进程具有重要价值。
Objective To investigate the clinical effect of Biejia Ruangan Tablets(BRT)combined with Entecavir(ETV)in the treatment of chronic hepatitis B(CHB).Methods A total of 174 CHB patients treated in People′s Hospital of Yichun City from September 2016 to December 2018 were selected as the research objects and divided into the control group and the observation group by random number table method,with 87 cases in each group.The control group was treated with ETV,and the observation group was treated with ETV and BRT.Liver inflammation grade,liver fibrosis grade,HBV DNA copy amount,serum alanine aminotransferase(ALT)and liver fibrosis index(hyaluronic acid[HA],typeⅢprocollagen[PCⅢ],typeⅣcollagen[Ⅳ-C],laminin[LN])levels in the two groups were compared.Results At the 48th week of treatment,the grade of liver inflammation in the two groups were better than those before treatment,and the differences were statistically significant(P<0.05).At the 48th week of treatment,there was no statistically significant difference in the grade of liver inflammation between the two groups(P>0.05).At the 48th week of treatment,the grade of liver fibrosis in the observation group was better than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no statistically significant differences in serum ALT,HA,PCⅢ,Ⅳ-C and LN levels between the two groups(P>0.05).At the 48th week of treatment,the levels of ALT,HA,PCⅢ,Ⅳ-C and LN in the two groups were lower than those before treatment,and the differences were statistically significant(P<0.05).At the 48th week of treatment,the levels of ALT,HA,PCⅢ,Ⅳ-C and LN in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There were no statistically significant differences in HBV DNA copy between the two groups before treatment,at the 12th,24th and 48th week of treatment(P>0.05).Conclusion BRT is an effective adjuvant therapy for CHB,and it is of great value in improving the process of liver fibrosis.
作者
孙秀光
徐娟
潘金平
SUN Xiu-guang;XU Juan;PAN Jin-ping(Department of Hepatology,People′s Hospital of Yichun City,Jiangxi Province,Yichun336000,China;Rehab Branch,People′s Hospital of Yichun City,Jiangxi Province,Yichun336000,China)
出处
《中国当代医药》
CAS
2021年第28期13-16,20,共5页
China Modern Medicine
基金
江西省卫生健康委员会科技计划项目(20197486)。
作者简介
孙秀光(1976-),男,汉族,副主任医师,主要从事病毒性肝炎方面的研究。
